FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Svennilson Peter   2. Issuer Name and Ticker or Trading Symbol Immune Design Corp. [IMDZ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E., SUITE 310 3. Date of Earliest Transaction (Month/Day/Year) 07/29/2014 (Street) SEATTLE, WA 98102 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/29/2014   C   733,943 A (1) 733,943 I (2) See Footnote (2) Common Stock 07/29/2014   C   744,580 A (1) 1,478,523 I (2) See Footnote (2) Common Stock 07/29/2014   C   856,269 A (1) 2,334,792 I (2) See Footnote (2) Common Stock 07/29/2014   C   428,134 A (1) 2,762,926 I (2) See Footnote (2) Common Stock 07/29/2014   P   399,016 A $ 12 3,161,942 I (2) See Footnote (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock	(1)	07/29/2014		C			733,943	(1)	(1)	Common Stock	733,943	$ 0	0	I (2)	See Footnote (2)
Series B Preferred Stock	(1)	07/29/2014		C			744,580	(1)	(1)	Common Stock	744,580	$ 0	0	I (2)	See Footnote (2)
Series C Preferred Stock	(1)	07/29/2014		C			856,269	(1)	(1)	Common Stock	856,269	$ 0	0	I (2)	See Footnote (2)
Series C Preferred Stock Warrant (right to buy)	$ 8.175	07/29/2014		X			428,134	10/16/2013	(3)	Series C Preferred Stock	428,134	$ 0	0	I (2)	See Footnote (2)
Series C Preferred Stock	(1)	07/29/2014		X		428,134		(1)	(1)	Common Stock	428,134	$ 0	428,134	I (2)	See Footnote (2)
Series C Preferred Stock	(1)	07/29/2014		C			428,134	(1)	(1)	Common Stock	428,134	$ 0	0	I (2)	See Footnote (2)

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Svennilson Peter C/O IMMUNE DESIGN CORP. 1616 EASTLAKE AVE. E., SUITE 310 SEATTLE, WA 98102	X	X

Signatures

/s/ Laura A. Berezin, Attorney-in-Fact		07/31/2014
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.
(2)	The securities are directly held by The Column Group, LP ("The Column Group") and indirectly held by The Column Group, GP, LP ("TCG GP"), the general partner of The Column Group. TCG GP has voting and dispositive power with respect to the shares owned by The Column Group. Mr. Svennilson is a managing partner of TCG GP and may be deemed to have shared voting and dispositive power over the shares owned by The Column Group. Mr. Svennilson disclaims beneficial ownership of all shares held by The Column Group, except to the extent of his actual pecuniary interest therein.
(3)	The warrants were set to expire on the earlier of: (a) October 15, 2015, (b) the latter of (i) 30 days after delivery to the warrant holder of the interim study report of a specified clinical trial by the Issuer or (ii) 30 days after notice to the warrant holder of the commencement of patient recruitment for specified studies or trials by the Issuer, (c) a liquidation event of the Issuer or (d) the closing of the Issuer's initial public offering.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.